Abstracts tagged "Lupus"

Abstract Number: 0891 • ACR Convergence 2021
Quality of Life Assessment in an Indian Inception Cohort (INSPIRE) of SLE Using Lupus QoL Questionnaire
Liza Rajasekhar¹, Dhundra Bhavani¹, Sneha Tota², Vishnupriya Vijayalekshmi³, Ranjan Gupta⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, VirSingh Negi⁷ and Amita Aggarwal², ¹NIMS, Hyderabad, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ³AIIMS, New delhi, delhi, India, ⁴AIIMS, New delhi, Ne Delhi, India, ⁵JIPMER, Pondicherry, India, ⁶Saint Johns Medical college, Bengaluru, Bengaluru, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
Background/Purpose: Lupus quality of life (Lupus QoL) questionnaire is a disease specific patient reported outcome that is available in multiple languages1. Indian SLE inception cohort…
Abstract Number: 1765 • ACR Convergence 2021
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?
Ewa Olech¹, Faizi Hussain² and Joan Merrill³, ¹IQVIA, Las Vegas, NV, ²IQVIA, Redding, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
Abstract Number: 0528 • ACR Convergence 2021
Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
Ilona Nln¹, Ruth Fernandez Ruiz², Theresa Wampler Muskardin³, Stephanie Tuminello², Mukundan Attur², Eduardo Itturate², Christopher Petrilli², Steven B. Abramson⁴, Aravinda Chakravarti² and Timothy Niewold¹, ¹Colton Center for Autoimmunity NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Type I interferon (IFN) is critical in our defense against viral infections. Increased type I IFN pathway activation is a genetic risk factor for…
Abstract Number: 0625 • ACR Convergence 2021
Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes
Shivani Garg¹, Betty Chewning¹, Shelby Gomez¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Up to 83% of SLE patients are nonadherent to hydroxychloroquine (HCQ) which can result in up to 8-fold higher risk of early death. Yet,…
Abstract Number: 0783 • ACR Convergence 2021
Transmission Disequilibrium Testing Meets Next Generation Sequencing: Applying TDT to Whole Genome Data in Childhood-Onset Systemic Lupus Erythematosus
Kathleen Vazzana¹, Anthony Musolf², Joan Bailey-Wilson³, Zuoming Deng³, Mariana Kaplan³ and Laura Lewandowski², ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)/Children's National Hospital, Washington, DC, ²NIAMS, NIH, Rockville, MD, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder that is more severe in children than adults. Due to aggressive disease in childhood-onset SLE…
Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Victoria Newsome ¹, Jodi Dingle ², Manda Mitchell ³, Thomas Brent Graham ⁴ and Alaina Davis⁵, ¹Nashville, ²Vanderbilt University Medical Center, Nashville, Tennessee, ³Nashville, Tennessee, ⁴Vanderbilt University Medical Center, Nashville, ⁵Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…
Abstract Number: 031 • 2020 Pediatric Rheumatology Symposium
Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?
Yike Jiang¹, Bo Yuan ¹, Marietta DeGuzman ¹, M. Cecilia Poli ², Justin Branch ¹, Andrea Ramirez ³, Martha Curry ¹, Maria Pereira ⁴, Amanda Brown ¹, W. Blaine Lapin ⁵, Sarah Nicholas ¹, Lisa Forbes ¹, Nicholas Rider ¹, Levi Watkin ¹, Jennifer Rammel ⁶, Ankur Kamdar ⁷, Melissa Mizesko ⁸, Juan Carlos Becerra ⁹, Emilina Lim ¹⁰, Eyal Muscal ¹¹, Anaid Reyes ¹, Zeynep Coban-Akdemir ¹, James Lupski ¹, Ivan Chinn ¹ and Tiphanie Vogel ¹, ¹Baylor College of Medicine, Houston, ²Universidad del Desarrollo, Santiago, Chile, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴Assistant Professor, Section of Rheumatology, Division of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁵, ⁶Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ⁷Houston, ⁸Driscoll Children's Hospital, Corpus Christi, ⁹Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, ¹⁰Children's Hospital Orange County, Orange County, ¹¹Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with multifactorial etiology. Identification of monogenic causes of pediatric SLE (pSLE) has yielded important insights…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
Abstract Number: 088 • 2020 Pediatric Rheumatology Symposium
Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting
Tamara Tanner¹, Gabriel Tarshish ², Dawn Wahezi ³ and Tamar Rubinstein ⁴, ¹Montefiore Medical Center, Bronx, ²Children's Hospital at Montefiore, New York, ³Children's Hospital at Montefiore, Bronx, ⁴Albert Einstein College of Medicine, White Plains
Background/Purpose: Exposure to sunlight has been implicated as a major contributing factor in the pathogenesis of systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM). Despite…
Abstract Number: 168 • 2020 Pediatric Rheumatology Symposium
Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
Keila Veiga¹, Noa Schwartz ², William Shipman ¹, Marvin Sandoval ³, Thomas Li ¹, Yurii Chinenov ¹, David Oliver ¹, Ali Jabbari ⁴, James Krueger ⁵, Sarah Taber ¹, Niroshana Anandasabapathy ⁶ and Theresa Lu ¹, ¹Hospital for Special Surgery, New York, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, ³Weill Cornell Graduate School of Medical Sciences, New York, ⁴University of Iowa, Iowa City, ⁵Rockefeller Center, New York, ⁶Weill Cornell Medicine, New York
Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus. Lesions can be disfiguring and have a negative impact on quality of…
Abstract Number: 244 • 2019 ACR/ARP Annual Meeting
Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Jennifer Lofland¹, Pamela Berry ², Feng Pan ², Chetan Karyekar ³, Hannah Guiang ⁴, Rebecca McTavish ⁴ and Melissa Thompson ⁴, ¹Janssen Scientific Affairs, LLC, Spring House, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Global Services, LLC, Horsham, PA, ⁴Cornerstone Research Group, Inc, Burlington, ON, Canada
Background/Purpose: SLE is an autoimmune multi-system disease characterized by flares and more rarely remissions. Emerging biologic therapies for SLE are expected to change the treatment…
Abstract Number: 1036 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery
Nicholas Young¹, Kyle Jablonski ², Ifeoma Okafor ³, Emily Schwarz ³, Peter Harb ³, Caitlin Henry ³, Lai-Chu Wu ³ and Wael Jarjour ⁴, ¹The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ³Ohio State College of Medicine, Columbus, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Studies examining intracellular micro-RNA (miR) expression in PBMCs of patients with Systemic Lupus Erythematous (SLE) have identified distinct disease-associated changes in expression. We have…
Abstract Number: 1618 • 2019 ACR/ARP Annual Meeting
Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity
Diane Apostolopoulos¹, Rangi Kandane-Rathnayake ¹, Worawit Louthrenoo ², Shue Fen Luo ³, Yeong-Jian Wu ³, Aisha Lateef ⁴, Vera Golder ¹, Sargunan Sockalingam ⁵, Sandra Navarra ⁶, Leonid Zamora ⁷, Laniyati Hamijoyo ⁸, Yasuhiro Katsumata ⁹, Masayoshi Harigai ⁹, Madelynn Chan ¹⁰, Sean O'Neill ¹¹, Fiona Goldblatt ¹², Chak Sing Lau ¹³, Alberta Hoi ¹⁴, Mandana Nikpour ¹⁵ and Eric Morand ¹⁶, ¹Monash University, Melbourne, Australia, ²Chiang Mai University Hospital, Chiang Mai, Thailand, ³Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), ⁴National University Hospital, Singapore, Singapore, ⁵University of Malaya, Kuala Lumpur, Malaysia, ⁶University of Santo Tomas Hospital, Manila, Philippines, ⁷Santo Tomas Hospital, Manila, Philippines, ⁸Padjadjaran University, Bandung, Indonesia, ⁹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹University of NSW, Ingham Institute of Applied Medical Research, Sydney, Australia, ¹²Royal Adelaide Hospital, Adelaide, Australia, ¹³Hong Kong University, Hong Kong, Hong Kong, ¹⁴School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ¹⁵St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, ¹⁶Monash University, Melbourne, Victoria, Australia
Background/Purpose: Accrual of irreversible organ damage is a major risk factor for death in SLE. While unmodifiable factors, such as age at disease onset and…
Abstract Number: 2564 • 2019 ACR/ARP Annual Meeting
Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus
Ji-Hyoun Kang¹, Seong-Eun Choi ¹, Haimuzi Xu ¹, Dong-Jin Park ¹ and Shin-Seok Lee ², ¹Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ²Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), decreasing the risk of flares and comorbidities and improving survival. This…
Abstract Number: 273 • 2019 ACR/ARP Annual Meeting
Bone Health in Lupus: Findings from the Southern California Lupus Registry
Vaneet Sandhu, MBBS¹ and Sara Johnson ², ¹Loma Linda University, Loma Linda, CA, ²St George's University, Loma Linda, CA
Background/Purpose: The association of vitamin D deficiency with SLE is well established. While disease activity can itself cause pathologic bone remodeling and reduced vitamin D,…

1
2
3
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].